Roivant Sciences, the biotech company once pitched as a Berkshire Hathaway for the pharmaceutical industry, is going public, merging with a blank-check company at a $7.3 billion valuation.

In a deal disclosed Monday, Roivant will combine with a special-purpose acquisition company, or SPAC, called Montes Archimedes Acquisition Corp., founded by private equity investor Jim Momtazee. Roivant gets the $411 million Montes raised in its initial public offering last year, plus another $200 million in new financing from a group of investors that includes Fidelity, Viking Global, SoftBank, and Palantir Technologies.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Source: STATNEWS.COM

Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]